TCM
VRTX icon

Triumph Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Triumph Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.6K Sell
112
-19
-15% -$8.42K 0.01% 649
2026
Q1 		$58.5K Buy
131
+15
+13% +$6.99K 0.01% 594
2025
Q4 		$52.6K Buy
+116
New +$50K 0.01% 601

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

Triumph Capital Management's VRTX Position: Q2 2026 in Review

Triumph Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 15% in Q2 2026, selling an estimated $8.42K and leaving 112 shares worth $55.6K. The position accounts for 0.01% of the portfolio, ranked #649.

Triumph Capital Management first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $58.5K in Q1 2026. 305 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Triumph Capital Management held 112 shares of Vertex Pharmaceuticals worth $55.6K as of Q2 2026.
  • Triumph Capital Management sold 19 Vertex Pharmaceuticals shares in Q2 2026, an estimated $8.42K.
  • Vertex Pharmaceuticals made up 0.01% of Triumph Capital Management's portfolio in Q2 2026, its #649 holding.
  • Triumph Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Triumph Capital Management's Vertex Pharmaceuticals position peaked at $58.5K in Q1 2026.
  • 305 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.